Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
Clinical trial NCT05700721 · RECRUITING
Trial details
- NCT number
- NCT05700721
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-02
- Primary completion
- 2029-12-31
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.